Abstract of the Disclosure

[0185]   The invention concerns methods for improvement of lung function by administering   non-peptide small molecule inhibitors of TGF-β specifically binding to the type I TGF-β receptor (TGFβ-R1).   Preferably, the inhibitors are quinazoline derivatives.